613656-45-4

Usage

Uses

Used in Recreational Settings:
1-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)-N-METHYLMETHANAMINE is used as a recreational substance for its stimulant and hallucinogenic effects, providing users with feelings of euphoria, altered perception, and heightened sensory experiences. However, it is important to note that its use is associated with harmful side effects and is classified as a Schedule I controlled substance in the United States due to its high potential for abuse and lack of accepted medical use.

Upstream product

• 593-51-1 methylamine hydrochloride 
• 29668-44-8 2,3-dihydro-benzo[1,4]dioxin-6-carbaldehyde 
• 74003-55-7 3,4-dibromobenzaldehyde 
• 139-85-5 3,4-dihydroxybenzaldehyde 
• 74-89-5 methylamine 

Downstream Products

• 929048-68-0 2-(3,4,5-trimethoxyphenyl)-2-acetoxy-N-methyl-N-(3,4-ethylenedioxybenzyl)-acetamide 

Relevant academic research and scientific papers

Oxygen-containing benzo-cycloaliphatic amine compounds

The invention provides an oxygen-containing benzo-cycloaliphatic substituted amine compounds and application thereof and specifically relates to the oxygen-containing benzo-cycloaliphatic substitutedamine compounds as shown in a formula I which is described in the specification or pharmaceutically acceptable salts thereof and application of the same to preparation of Staphylococcus aureus goldenpigment synthesis inhibitor type antibacterial agents.

Novel Staphyloxanthin Inhibitors with Improved Potency against Multidrug Resistant Staphylococcus aureus

Diapophytoene desaturase (CrtN) is a potential novel target for intervening in the biosynthesis of the virulence factor staphyloxanthin. In this study, 38 1,4-benzodioxan-derived CrtN inhibitors were designed and synthesized to overwhelm the defects of leading compound 4a. Derivative 47 displayed superior pigment inhibitory activity, better hERG inhibitory properties and water solubility, and significantly sensitized MRSA strains to immune clearance in vitro. Notably, 47 displayed excellent efficacy against pigmented S. aureus Newman, Mu50 (vancomycin-intermediate MRSA, VISA), and NRS271 (linezolid-resistant MRSA, LRSA) comparable to that of linezolid and vancomycin in vivo.

Isoquinolines as IGF-1R Inhibitors

Compounds of the formula (I): were synthesized. In at least one embodiment, they were found to down-regulate or inhibit the expression or function of the IGF-1 receptor.

ISOQUINOLINES AS IGF-1R INHIBITORS

Compounds of the formula (I) were synthesized. They were found to down- regulate or inhibit the expression or function of the IGF-I receptor.

HETEROCYCLIC COMPOUNDS, METHODS OF MAKING THEM AND THEIR USE IN THERAPY

In part, the present invention is directed to antibacterial compounds of formula (I) wherein A is a bicyclic heteroaryl ring or a tricyclic ring and R2 is an heterocyclic residue; L is a bond, or L is alkyl, alkenyl or cycloalkyl.